Current Role

Senior Biostatistician specialising in clinical trials in Oncology and Cardiovascular disease.

Key responsibilities

• creating statistical designs for clinical trials
• conducting corresponding statistical analyses
• generating statistical reports of clinical trial findings
• preparing manuscripts for external peer review publication
• contributing to grant applications for funding
• preparing ethics committee submissions.

Key research interests

• Flexible parametric survival modelling
• Modelling of zero-inflated data

Publishing Highlights

• Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet, Volume 395, Issue 10231, 11–17 April 2020, Pages 1208-1216

Impact: Concluded that novel imaging using prostate-specific membrane antigen (PSMA) PET-CT improves accuracy and management of high-risk localised prostate cancer.

• Optimising area under the ROC curve using gradient descent. ICML '04: Proceedings of the twenty-first international conference on Machine learning

Impact: Introduced a linear binary classifier which optimises the area under the ROC curve adopting the AUC statistic as its objective function.

• Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. The Lancet Oncology, Volume 20, Issue 4, April 2019, Pages 494-503

Impact: Concluded that in patients with inoperable peripherally located stage 1 NSCLC, compared with standard radiotherapy, SABR (Stereotactic Ablative Body Radiotherapy) resulted in superior local control of the primary disease without an increase in major toxicity.